Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

Francesco Perna, Cesare Hassan, V De Francesco, A Zullo, E Ierardi, F Giorgio, S Morini, C Panella, D. Vaira

Risultato della ricerca: Contributo in rivistaArticolo in rivista

78 Citazioni (Scopus)

Abstract

Primary clarithromycin resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. However, the clinical consequence of either phenotypic or genotypic resistance still remains unclear. This study aimed to evaluate: (i) the concordance between phenotypic (culture) and genotypic (real-time PCR) tests in assessing primary clarithromycin resistance; and (ii) the role of both in therapeutic outcome.
Lingua originaleEnglish
pagine (da-a)327-332
Numero di pagine6
RivistaJournal of Antimicrobial Chemotherapy
Volume65
DOI
Stato di pubblicazionePubblicato - 2010

Keywords

  • Adult
  • Anti-Bacterial Agents
  • Breath Tests
  • Clarithromycin
  • DNA, Bacterial
  • DNA, Ribosomal
  • Drug Resistance, Bacterial
  • Female
  • Gastric Mucosa
  • Helicobacter Infections
  • Helicobacter pylori
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Point Mutation
  • Polymerase Chain Reaction
  • RNA, Ribosomal, 23S
  • Treatment Outcome
  • Urease

Fingerprint

Entra nei temi di ricerca di 'Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits'. Insieme formano una fingerprint unica.

Cita questo